SUMMARY Nine patients with hypertrophic cardiomyopathy associated with Friedreich's ataxia were treated with the calcium antagonist verapamil, which is known to reduce myocardial hypertrophy and improve diastolic function in patients with idiopathic hypertrophic cardiomyopathy. Daily oral doses of 7mg/kg were given for a mean (SD) of 24 (8) 
Left ventricular hypertrophy (usually concentric and non-obstructive) has been found in 38% to 67% of patients with Friedreich's ataxia.' 3 In a series of 18 cases our own group found echocardiographic evidence of concentric left ventricular hypertrophy in 39% of cases and asymmetric (non-obstructive) hypertrophy in 33%.' St John Sutton et al found reduced diastolic function in most of their patients with Friedreich's ataxia. 5 Calcium antagonists have been effective in other forms of hypertrophic cardiomyopathy. Kaltenbach et al gave oral verapamil (480mg daily) for more than a year to patients with obstructive hypertrophic cardiomyopathy.6 They found that QRS voltage, heart volume (determined radiologically), and left ventricular mass (determined haemodynamically) were reduced. Hirzel et al confirmed these findings7; as did Spicer et al in children. 8 Verapamil has also been reported to improve left ventricle relaxation and filling in adults and children with hypertrophic cardiomyopathy. 8 10 Other evidence encourages the use of calcium an- 
Discussion
Our results are at variance with those reported by other workers who used similar doses of verapamil to treat patients with hypertrophic cardiomyopathy.5 6 8 22 We found that long term treatment with verapamil of patients with cardiomyopathy as- Table 4 Statistical comparison (covariance analysis*) of echocardiographic variables at the beginning and at the end of follow up in patients who were treated with verapamil and those who were not LV mass index (gWm2) 111-9 (26) 112-8 (18) 124-3 (41) 108-1 (17) FS% 34-1 (8 3) 36-2 ( 7 6) 35-1 (5-7) 36-8 (7 6) LA/AO 
9-8 ( 4 5) 6-8 ( 2 7) *None of the variables was significantly different. See Table 1 Our results do not support the hypothesis that intramyocardial calcium accumulation is an important factor in the pathogenesis of cardiac disease in Friedreich's ataxia. Although the hypothesis rests on apparently good experimental evidence, the fact remains that verapamil did not reduce established myocardial hypertrophy. The role of calcium accumulation in the pathogenesis of myocardial hypertrophy in patients with Friedreich's ataxia can probably only be established by a study in which verapamil is given early in the course of disease, when neurological and cardiac signs and symptoms are just beginning to appear-that is, before myocardial cells are replaced by fibrotic tissue.9 24 Our data on basal diastolic function accord broadly with those reported by St John Sutton et al in a study of seven patients with Friedreich's ataxia.'
All patients with hypertrophic cardiomyopathy (groups 1 and 2) had a highly significant reduction of the posterior wall thinning peak rate and a significant reduction in septal thinning rate compared with normal subjects. The 25 26 In conclusion, long term oral treatment with verapamil at high doses was readily tolerated by all our patients. In particular, there was no deterioration of left ventricular systolic function or evidence of heart failure. Verapamil, a calcium antagonist, did not reduce left ventricular wall thickness, possibly because interstitial fibrosis in these patients with Friedreich's ataxia was already advanced. Left ventricular diastolic function was not significantly improved by long term verapamil treatment.
In our opinion routine verapamil treatment is not justified in symptom free patients who have Friedreich's ataxia complicated by hypertrophic cardiomyopathy. Alone or in association with other drugs, however, verapamil might be useful in the treatment of supraventricular tachyarrhythmia in selected cases. 
